FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Stark David Matthew 2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2018 3. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA] (Last) (First) (Middle) C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Exec. VP Chief Legal Officer 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) PETACH TIKVA, L3 4951033 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares (1) 2,974.39 D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	  (2)	11/06/2021	Ordinary Shares (1)	6,668	$ 41.72	D	Â
Stock Options (right to buy)	  (3)	02/23/2022	Ordinary Shares (1)	5,335	$ 44.59	D	Â
Stock Options (right to buy)	  (4)	12/12/2022	Ordinary Shares (1)	6,668	$ 38.84	D	Â
Stock Options (right to buy)	  (5)	02/23/2023	Ordinary Shares (1)	6,668	$ 38.08	D	Â
Stock Options (right to buy)	  (6)	03/11/2024	Ordinary Shares (1)	15,002	$ 48.76	D	Â
Stock Options (right to buy)	  (7)	03/11/2025	Ordinary Shares (1)	51,308	$ 60.21	D	Â
Stock Options (right to buy)	  (8)	03/16/2026	Ordinary Shares (1)	50,006	$ 53.5	D	Â
Stock Options (right to buy)	  (9)	02/14/2027	Ordinary Shares (1)	62,364	$ 34.9	D	Â
Restricted Share Units	  (10)	  (10)	Ordinary Shares (1)	4,885	$ (11)	D	Â
Restricted Share Units	  (12)	  (12)	Ordinary Shares (1)	7,075	$ (11)	D	Â
Restricted Share Units	  (13)	  (13)	Ordinary Shares (1)	11,778	$ (11)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Stark David Matthew C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA, L3 4951033	Â	Â	  Exec. VP Chief Legal Officer	Â

Signatures

/s/ Dov Bergwerk, as attorney-in-fact for David M. Stark		01/02/2018
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)	Stock options were granted on November 7, 2011 and vested on November 7, 2015.
(3)	Stock options were granted on February 24, 2012 and vested on February 24, 2016.
(4)	Stock options were granted on December 13, 2012 and vested on December 13, 2015.
(5)	Stock options were granted on February 24, 2013 and vested on February 24, 2016.
(6)	Stock options were granted on March 12, 2014, with 7,501 having vested on each of March 12, 2016 and March 12, 2017.
(7)	Stock options were granted on March 12, 2015, with 12,827 having vested on each of March 12, 2016 and March 12, 2017 and 12,827 vesting on each of March 12, 2018 and March 12, 2019.
(8)	Stock options were granted on March 17, 2016, with 12,501 having vested on March 17, 2017, 12,501 vesting on each of March 17, 2018 and March 17, 2019 and 12,503 vesting on March 17, 2020.
(9)	Stock options were granted on February 14, 2017, with 20,788 vesting on each of February 14, 2019, February 14, 2020 and February 14, 2021.
(10)	Restricted share units were granted on March 12, 2015, with 2,441 vesting on March 12, 2018 and 2,444 vesting on March 12, 2019.
(11)	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
(12)	Restricted share units were granted on March 17, 2016, with 2,358 vesting on each of March 17, 2018 and March 17, 2019 and 2,359 vesting on March 17, 2020.
(13)	Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2019, February 14, 2020 and February 14, 2021.
  Remarks: The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018. Exhibit List      Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.